Developer docs
API playgroundTry for free, no card

Search company profiles

Evoq Technologies

Full company profile

uuid0008pbb

Namestring
Evoq Technologies
Legal namestring
Evoq Technologies Corp
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Evoq Technologies Corp is a privately held medical device company (Delaware corporation, Henderson, Nevada HQ, founded 2023 with operational lineage through Xenotec and OcuScience) that designs and sells smartphone-based wearable biosensor diagnostic devices for early detection of retinal dysfunction. Its product portfolio centers on the SmartERG® smartphone electrophysiology platform (FDA approval received November 2024), the Twilight™ FDA-registered Class I dark adaptometer (launched November 2025), and the SightGard™ platform that integrates these functional tests into routine eye care workflows for conditions including age-related macular degeneration, diabetic eye disease, and inherited retinal diseases.

The underlying technology replaces legacy desktop ERG and dark-adaptation instruments with portable, technician-led hardware paired to a smartphone, marketed to MD, OD, PhD, and DVM researchers and clinicians as a cost-effective alternative for evoked-response electrophysiology spanning vision, auditory, neurology, and physical therapy applications. The company holds FDA Operator Number 10083427 and is pursuing investigator-led clinical validation studies through its Scientific Advisory Board.

Evoq generates revenue primarily through direct hardware sales via its Shopify storefront (evoqtech.myshopify.com) and is actively soliciting licensing and partnership deals with medical device, pharmaceutical, and health delivery partners. Go-to-market mixes e-commerce, conference-driven field sales (ARVO, AAO, Vision Expo), and relationship development with healthcare providers. The company operates only in the United States today, has 11–50 employees, and discloses no revenue, funding rounds, or capital structure in the available data.

Short descriptiontext

Evoq Technologies Corp is a privately held medical device company that builds smartphone-based wearable biosensor diagnostics — including the FDA-cleared SmartERG platform, Twilight dark adaptometer, and SightGard platform — to enable early detection of retinal dysfunction for eye care professionals, researchers, and at-risk patients in the United States.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHenderson, United States
HQ citystring
Henderson
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmic diagnostic devices, medical-grade biosensors, retinal electrophysiology, dark adaptometry, wearable medical devices
Industry4 codes
PRIMARYHLAHAJAC
Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHDAHAAAG
Sensors, MEMS & Imaging ICs
SECONDARYHDAHALAE
Optical & Light Sensors (Photodiodes/ALS/Color/UV)
NAICS code4 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
  • Instrument Manufacturing for Measuring and Testing Electricity and Electrical Signals334515
  • Other Measuring and Controlling Device Manufacturing334519
SIC code4 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Instruments For Meas & Testing Of Electricity & Elec Signals3825
  • Optical Instruments & Lenses3827
  • Laboratory Analytical Instruments3826
Product category
Ophthalmic Diagnostic Medical Devices
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales
TypeHardware Sales
Description

Evoq Technologies generates revenue through the sale of FDA-registered medical devices including the SmartERG platform and Twilight Dark Adaptometer. Products are sold directly through the company's e-commerce storefront and are available for purchase in the United States.

goevoq.com
2Licensing and Partnerships
TypeLicensing Royalties
Description

Evoq Technologies seeks licensing and partnership opportunities with medical device, pharmaceutical, and health delivery stakeholders who want to lead the future in function-first diagnostics. The company is open to licensing its proprietary technology platforms.

goevoq.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Twilight
Description

FDA-registered Class I medical device for dark adaptation testing in eye care diagnostics

goevoq.com
+2 more records
Core offering1 text field

Evoq Technologies develops and sells FDA-registered medical-grade wearable biosensor diagnostic devices for early detection of retinal dysfunction. Its core offerings include the Twilight™ Dark Adaptometer (Class I medical device) and the SmartERG® smartphone-based electrophysiology system, unified under the SightGard™ platform, enabling portable, technician-led functional vision testing in clinical and home settings as a cost-effective alternative to legacy desktop ERG equipment.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Twilight enables fast, technician-led dark adaptation tests in any clinical setting without specialized dark rooms
+2 more records
Product overview1 text field

Evoq Technologies offers a portfolio of medical-grade wearable biosensor diagnostic devices and platforms focused on early detection of retinal dysfunction and vision diseases. The core product lineup includes the Twilight™ Dark Adaptometer (FDA-registered Class I device for dark adaptation testing), the SmartERG® smartphone-based electrophysiology system (FDA-registered), and the SightGard™ platform integrating functional testing into routine care. The SightGard platform serves as the overarching diagnostic framework, with Twilight and SmartERG representing the specific device families within it.

Product and service2 records
1Twilight™ Dark Adaptometer
CategoryOphthalmic diagnostic medical device
Description

FDA-registered Class I medical device that performs dark adaptation tests faster and without specialized dark rooms, enabling earlier detection of visual dysfunction related to age-related macular degeneration (AMD), diabetic eye disease, and inherited retinal diseases; sold to eye care professionals and available direct to consumers via the company's e-commerce storefront in the United States.

2SmartERG® Smartphone-Based Electrophysiology System
CategoryOphthalmic and neurophysiology diagnostic medical device
Description

FDA-approved smartphone-based electrophysiology system that tests retinal health and supports evoked response electrophysiology for vision, auditory, neurology, and physical therapy applications; positioned as a cost-effective, portable alternative to legacy desktop electrophysiology devices for MD, OD, PhD, and DVM researchers, technologists, and clinicians.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Konan Medical (which acquired LKC Technologies' dark adaptometry line) provides specialty ophthalmic diagnostic devices including dark adaptometers and electrophysiology tools, directly comparable to Evoq's Twilight and SmartERG.

TypeBroad incumbent
Description

Heidelberg Engineering is a major ophthalmic diagnostic incumbent selling OCT, perimetry, and imaging systems. It competes indirectly by bundling diagnostic modalities and could extend into portable ERG/dark adaptation, posing a competitive threat to Evoq's niche.

TypeBroad incumbent
Description

Reichert, part of AMETEK, manufactures ophthalmic diagnostic instruments including tonometers, refractors, and lensometers. It is a broad incumbent in clinical eye diagnostics with overlap in functional testing categories.

TypeBroad incumbent
Description

iCare (which acquired CenterVue) makes fundus imaging, perimetry, and tonometry devices for ophthalmology. It is a broad incumbent with adjacent functional testing products relevant to Evoq's diagnostic positioning.

TypeBroad incumbent
Description

Topcon Healthcare is a global ophthalmic device incumbent offering imaging, perimetry, and diagnostic instruments. It is a broad incumbent whose portfolio overlaps with the diagnostic categories Evoq is targeting.

6Carl Zeiss Meditec
TypeBroad incumbent
Description

Carl Zeiss Meditec is one of the largest ophthalmic device companies globally, offering OCT, perimetry, and other diagnostic systems. It is a broad incumbent whose resources dwarf Evoq's and could enter portable electrophysiology.

TypeDirect peer
Description

LKC Technologies manufactures the AdaptDx dark adaptometer and other visual electrophysiology devices used in AMD detection. It directly competes with Evoq's Twilight Dark Adaptometer in the dark adaptation and ERG market.

TypeBroad incumbent
Description

Nidek is a Japanese ophthalmic equipment manufacturer offering a wide range of diagnostic and refractive devices. Comparable as a broad incumbent in ophthalmic diagnostics that could expand into portable ERG or dark adaptation.

TypeDirect peer
Description

Diopsys is a U.S. medical device company specializing in visual electrophysiology, including ERG and VEP systems used in ophthalmology and optometry. It is the most direct competitor to Evoq's SmartERG in clinical electrophysiology diagnostics.

TypeDirect peer
Description

Diagnosys is a direct peer in visual electrophysiology, providing desktop and clinical ERG, VEP, and dark adaptation systems for ophthalmology research and clinical use. Overlaps with Evoq's evoked response and dark adaptation offerings.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Evoq Technologies

Ophthalmic Diagnostic Medical Devicesevoqtechnologies.com

Evoq Technologies Corp is a privately held medical device company that builds smartphone-based wearable biosensor diagnostics — including the FDA-cleared SmartERG platform, Twilight dark adaptometer, and SightGard platform — to enable early detection of retinal dysfunction for eye care professionals, researchers, and at-risk patients in the United States.

What Evoq Technologies does

Evoq Technologies Corp is a privately held medical device company (Delaware corporation, Henderson, Nevada HQ, founded 2023 with operational lineage through Xenotec and OcuScience) that designs and sells smartphone-based wearable biosensor diagnostic devices for early detection of retinal dysfunction. Its product portfolio centers on the SmartERG® smartphone electrophysiology platform (FDA approval received November 2024), the Twilight™ FDA-registered Class I dark adaptometer (launched November 2025), and the SightGard™ platform that integrates these functional tests into routine eye care workflows for conditions including age-related macular degeneration, diabetic eye disease, and inherited retinal diseases.

The underlying technology replaces legacy desktop ERG and dark-adaptation instruments with portable, technician-led hardware paired to a smartphone, marketed to MD, OD, PhD, and DVM researchers and clinicians as a cost-effective alternative for evoked-response electrophysiology spanning vision, auditory, neurology, and physical therapy applications. The company holds FDA Operator Number 10083427 and is pursuing investigator-led clinical validation studies through its Scientific Advisory Board.

Evoq generates revenue primarily through direct hardware sales via its Shopify storefront (evoqtech.myshopify.com) and is actively soliciting licensing and partnership deals with medical device, pharmaceutical, and health delivery partners. Go-to-market mixes e-commerce, conference-driven field sales (ARVO, AAO, Vision Expo), and relationship development with healthcare providers. The company operates only in the United States today, has 11–50 employees, and discloses no revenue, funding rounds, or capital structure in the available data.

Evoq Technologies firmographics

Firmographics
Name
Evoq Technologies
Legal name
Evoq Technologies Corp
Website
https://evoqtechnologies.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
Evoq Technologies Corp is a privately held medical device company that builds smartphone-based wearable biosensor diagnostics — including the FDA-cleared SmartERG platform, Twilight dark adaptometer, and SightGard platform — to enable early detection of retinal dysfunction for eye care professionals, researchers, and at-risk patients in the United States.
Ownership category
akta.pro rank

Evoq Technologies industry classification

Industry
Product category
Ophthalmic Diagnostic Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Instrument Manufacturing for Measuring and Testing Electricity and Electrical Signals (334515), Other Measuring and Controlling Device Manufacturing (334519)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Instruments For Meas & Testing Of Electricity & Elec Signals (3825), Optical Instruments & Lenses (3827), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAHAJAC
Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHDAHAAAG
Sensors, MEMS & Imaging ICs
SECONDARYHDAHALAE
Optical & Light Sensors (Photodiodes/ALS/Color/UV)

Keywords

  • Ophthalmic diagnostic devices
  • Medical-grade biosensors
  • Retinal electrophysiology
  • Dark adaptometry
  • Wearable medical devices

Where Evoq Technologies is headquartered

Location

Headquarters

HQ city
Henderson
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Evoq Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Medical Device Sales: Evoq Technologies generates revenue through the sale of FDA-registered medical devices including the SmartERG platform and Twilight Dark Adaptometer. Products are sold directly through the company's e-commerce storefront and are available for purchase in the United States.
  2. Licensing and Partnerships: Evoq Technologies seeks licensing and partnership opportunities with medical device, pharmaceutical, and health delivery stakeholders who want to lead the future in function-first diagnostics. The company is open to licensing its proprietary technology platforms.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Evoq Technologies product offering

Product offering

Core offering

Evoq Technologies develops and sells FDA-registered medical-grade wearable biosensor diagnostic devices for early detection of retinal dysfunction. Its core offerings include the Twilight™ Dark Adaptometer (Class I medical device) and the SmartERG® smartphone-based electrophysiology system, unified under the SightGard™ platform, enabling portable, technician-led functional vision testing in clinical and home settings as a cost-effective alternative to legacy desktop ERG equipment.

Product overview

Evoq Technologies offers a portfolio of medical-grade wearable biosensor diagnostic devices and platforms focused on early detection of retinal dysfunction and vision diseases. The core product lineup includes the Twilight™ Dark Adaptometer (FDA-registered Class I device for dark adaptation testing), the SmartERG® smartphone-based electrophysiology system (FDA-registered), and the SightGard™ platform integrating functional testing into routine care. The SightGard platform serves as the overarching diagnostic framework, with Twilight and SmartERG representing the specific device families within it.

Differentiator

Problem solved

Functional benefit

Brands

  • Twilight: FDA-registered Class I medical device for dark adaptation testing in eye care diagnostics
  • SmartERG
  • SightGard

Products and services

  • Twilight™ Dark Adaptometer FDA-registered Class I medical device that performs dark adaptation tests faster and without specialized dark rooms, enabling earlier detection of visual dysfunction related to age-related macular degeneration (AMD), diabetic eye disease, and inherited retinal diseases; sold to eye care professionals and available direct to consumers via the company's e-commerce storefront in the United States.
  • SmartERG® Smartphone-Based Electrophysiology System FDA-approved smartphone-based electrophysiology system that tests retinal health and supports evoked response electrophysiology for vision, auditory, neurology, and physical therapy applications; positioned as a cost-effective, portable alternative to legacy desktop electrophysiology devices for MD, OD, PhD, and DVM researchers, technologists, and clinicians.

Quantifiable outcome

  • Twilight enables fast, technician-led dark adaptation tests in any clinical setting without specialized dark rooms
  • +2 more outcomes

Companies that use Evoq Technologies

Customer profile

Segments3 records

Ideal customer profiles4 records

Evoq Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Evoq Technologies partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Evoq Technologies competitors and assessment

Company assessment

Direct peers

  • Konan Medical: Konan Medical (which acquired LKC Technologies' dark adaptometry line) provides specialty ophthalmic diagnostic devices including dark adaptometers and electrophysiology tools, directly comparable to Evoq's Twilight and SmartERG.
  • LKC Technologies: LKC Technologies manufactures the AdaptDx dark adaptometer and other visual electrophysiology devices used in AMD detection. It directly competes with Evoq's Twilight Dark Adaptometer in the dark adaptation and ERG market.
  • Diopsys: Diopsys is a U.S. medical device company specializing in visual electrophysiology, including ERG and VEP systems used in ophthalmology and optometry. It is the most direct competitor to Evoq's SmartERG in clinical electrophysiology diagnostics.
  • Diagnosys LLC: Diagnosys is a direct peer in visual electrophysiology, providing desktop and clinical ERG, VEP, and dark adaptation systems for ophthalmology research and clinical use. Overlaps with Evoq's evoked response and dark adaptation offerings.

Broad incumbents

  • Heidelberg Engineering: Heidelberg Engineering is a major ophthalmic diagnostic incumbent selling OCT, perimetry, and imaging systems. It competes indirectly by bundling diagnostic modalities and could extend into portable ERG/dark adaptation, posing a competitive threat to Evoq's niche.
  • Reichert Technologies (AMETEK): Reichert, part of AMETEK, manufactures ophthalmic diagnostic instruments including tonometers, refractors, and lensometers. It is a broad incumbent in clinical eye diagnostics with overlap in functional testing categories.
  • iCare (including CenterVue): iCare (which acquired CenterVue) makes fundus imaging, perimetry, and tonometry devices for ophthalmology. It is a broad incumbent with adjacent functional testing products relevant to Evoq's diagnostic positioning.
  • Topcon Healthcare: Topcon Healthcare is a global ophthalmic device incumbent offering imaging, perimetry, and diagnostic instruments. It is a broad incumbent whose portfolio overlaps with the diagnostic categories Evoq is targeting.
  • Carl Zeiss Meditec: Carl Zeiss Meditec is one of the largest ophthalmic device companies globally, offering OCT, perimetry, and other diagnostic systems. It is a broad incumbent whose resources dwarf Evoq's and could enter portable electrophysiology.
  • Nidek Co., Ltd. Nidek is a Japanese ophthalmic equipment manufacturer offering a wide range of diagnostic and refractive devices. Comparable as a broad incumbent in ophthalmic diagnostics that could expand into portable ERG or dark adaptation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Evoq Technologies social profiles

Digital presence

Evoq Technologies compliance and trust

Trust signal

Compliance2 records

Evoq Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Evoq Technologies leadership team

Management profile

Number of profiles

Profiles2 records

Evoq Technologies funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Evoq Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Evoq Technologies

What does Evoq Technologies do?

Evoq Technologies develops and sells FDA-registered medical-grade wearable biosensor diagnostic devices for early detection of retinal dysfunction. Its core offerings include the Twilight™ Dark Adaptometer (Class I medical device) and the SmartERG® smartphone-based electrophysiology system, unified under the SightGard™ platform, enabling portable, technician-led functional vision testing in clinical and home settings as a cost-effective alternative to legacy desktop ERG equipment.

Is Evoq Technologies a public or private company?

Evoq Technologies is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Evoq Technologies founded?

Evoq Technologies was founded in 2023. It employs 11 to 50 people.

Where is Evoq Technologies based?

Evoq Technologies is headquartered in Henderson, United States, in the North America region.

How does Evoq Technologies make money?

Two revenue lines are on record. Medical Device Sales are the primary driver. The others are licensing and Partnerships.

Who are Evoq Technologies's main competitors?

Direct peers on record are Konan Medical, LKC Technologies, Diopsys and Diagnosys LLC. Broad incumbents are Heidelberg Engineering, Reichert Technologies (AMETEK), iCare (including CenterVue), Topcon Healthcare, Carl Zeiss Meditec and Nidek Co., Ltd..

Does Evoq Technologies have an API?

No public API is recorded for Evoq Technologies.

What industry is Evoq Technologies in?

Evoq Technologies's product category is Ophthalmic Diagnostic Medical Devices. Its primary akta.pro industry code is HLAHAJAC, Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity), with a secondary code of HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Eyes On EyecareEVOQ Technologies receives US patent for mobile retinal function testingThe USPTO has issued EVOQ Technologies U.S. Patent No. 12,685,439 for a smartphone-based retinal function testing system that provides controlled luminous stimulation directly to the eye and records ocular electrical signals via a connected wireless biosensor. The patent covers the core technology behind the company's SmartERG device, which uses a mobile device's LED flash and display as a photostimulator while a wearable biosensor captures electrophysiological responses for waveform display and retinal evaluation. The company, headquartered in Henderson, Nevada, is now seeking strategic partnerships and licensing opportunities for its portable retinal physiology technology.Eyes On EyecareEvoq launches FDA-registered dark adaptation testing device for IRDsEvoq Technologies announced the U.S. commercial launch of Twilight, a smartphone-based dark adaptation testing device for monitoring inherited retinal diseases (IRDs) and other retinal conditions. The device has received FDA Class I medical device registration and is associated with CPT code 92284 for reimbursement. Designed for both at-home patient tracking and clinical use, it aims to streamline functional vision assessments without requiring specialized equipment.EIN PresswireEvoq Technologies Launches Twilight™: A Breakthrough, FDA-Registered Class I Medical DeviceEvoq Technologies announced the official launch and FDA registration of Twilight™, a Class I medical device for dark adaptation testing that detects visual dysfunction linked to age-related macular degeneration, diabetic eye disease, and inherited retinal diseases. The device enables eye care professionals to perform fast, technician-led diagnostic tests in any clinical setting without specialized dark rooms or pupil dilation, eliminating workflow disruption. The product is now available for sale in the United States, with CPT 92284 being reimbursable for qualifying patients.EIN PresswireEvoq Technologies’ Breakthroughs in Retinal Diagnostics at AAO Annual MeetingEvoq Technologies showcased its Twilight™ dark adaptometer at the AAO Annual Meeting in Orlando, Florida from October 17-20, 2025, marking a featured presence in the AAO Innovation Hub alongside expanding clinical programs. The Twilight device is the first self-guided, wearable diagnostic that quantifies night vision loss to enable earlier detection of retinal dysfunction, including age-related macular degeneration. The company is enrolling investigator-initiated studies as it scales its SightGard™ platform for early retinal diagnostics.EIN PresswireEvoq Technologies Appoints Benjamin A. Bakall, MD, PhD as Scientific Advisor and Principal InvestigatorEvoq Technologies announced the appointment of Benjamin A. Bakall, MD, PhD as Scientific Advisor and Principal Investigator for clinical studies involving the Twilight Dark Adaptometer. Dr. Bakall, a practicing retina specialist and founder of the Retina Research Foundation of America, will guide the company's function-first diagnostic pipeline and lead real-world validation of the device. The appointment reinforces Evoq's focus on advancing early detection of retinal dysfunction through its SightGard platform.Business Wire BlogEvoq Technologies LLC Announces Launch of First Smartphone-Based Product for Retinal Health TestingEvoq Technologies announced FDA registration of its first smartphone-based retinal health testing device, the SmartERG platform, for dark adaptation impairment testing. The company plans clinical evaluations in 2022 for class II medical device submission. It seeks licensing and partnership opportunities with medical device and pharmaceutical stakeholders.